Ikena Oncology Stock (NASDAQ:IKNA)
Previous Close
$1.61
52W Range
$1.22 - $2.30
50D Avg
$1.70
200D Avg
$1.60
Market Cap
$74.80M
Avg Vol (3M)
$69.67K
Beta
0.48
Div Yield
-
IKNA Company Profile
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
IKNA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| STOK | Stoke Therapeutics, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| NRIX | Nurix Therapeutics, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| FHTX | Foghorn Therapeutics Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| MNOV | MediciNova, Inc. |
| RZLT | Rezolute, Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| XLO | Xilio Therapeutics, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| STTK | Shattuck Labs, Inc. |
| CELC | Celcuity Inc. |